Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5867154 | 0.71 | DPP4 (0.34) | DPP4 | |
| SCHEMBL11148134 | 0.69 | — | — | |
| SCHEMBL5867044 | 0.68 | DPP4 (0.35) | DPP4 | |
| SCHEMBL11146874 | 0.65 | — | — | |
| SCHEMBL1021003 | 0.64 | DPP4 (0.50) | DPP4 | |
| SCHEMBL5745750 | 0.64 | DPP4 (0.50) | DPP4 | |
| SCHEMBL19313345 | 0.64 | — | — | |
| SCHEMBL11143449 | 0.60 | — | — | |
| SCHEMBL4816382 | 0.59 | — | — | |
| SCHEMBL25664685 | 0.56 | DPP4 (0.39) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138416-B2 | Dipeptidyl peptidase inhibitors; heterocyclic amide and semicarbazide derivatives, e.g., (2-Cyano-1-(piperazine-2-yl)-carbonyl pyrrolidine bis-trifluoroacetate | TORRENT PHARMACEUTICALS LTD. (IN) | 2006-11-21 | — | — | US | disclosed |
| EP-1492777-A1 | THIAZOLIDINE-4-CARBONITRILES AND ANALOGUES AND THEIR USE AS DIPEPTIDYL-PEPTIDASE INHIBITORS | Torrent Pharmaceuticals Ltd (IN) | 2005-01-05 | — | — | EP | disclosed |
| US-20040106802-A1 | Novel compounds and therapeutic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2004-06-03 | — | — | US | disclosed |
| US-20030225102-A1 | Novel compounds and therapeutic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2003-12-04 | — | — | US | disclosed |
| WO-2003084940-A1 | THIAZOLIDINE-4-CARBONITRILES AND ANALOGUES AND THEIR USE AS DIPEPTIDYL-PEPTIDAS INHIBITORS | SANKARANARAYANAN ALANGUDI (IN) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225102-A1 | Novel compounds and therapeutic uses thereof | GPR119, SLC5A1, SLC2A4 | DPP4 192/4885 |
| US-20040106802-A1 | Novel compounds and therapeutic uses thereof | GPR119, SLC5A1, SLC2A3 | DPP4 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.